Is Corteva (CTVA) Still Attractive After A 45% One Year Share Price Surge

• Wondering if Corteva at around US$83.96 is priced for opportunity or already fully valued? This article walks through the key signals that can help you judge that for yourself.
• The stock has returned 0.2% over the past week, 7.2% over 30 days, 23.9% year to date, and 44.8% over the last year, which naturally raises questions about what is already baked into the price.
• Recent attention on Corteva has focused on its position within the broader materials and agriculture space and how investors are weighing its role in long term food production trends. This backdrop is a useful lens for thinking about whether the current share price simply reflects sentiment or lines up with underlying fundamentals.
• Despite that share price performance, Corteva currently records a valuation score of 0 out of 6. The next sections will break down what that means across different valuation methods, then finish with a way to pull those pieces together into a single, clearer view of value.

Corteva scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Corteva Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts them back to today to estimate what the business might be worth right now.

For Corteva, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow sits at about $2.8b. Analyst inputs and subsequent extrapolations suggest free cash flow in 2029 of around $2.6b, with intermediate projections between 2026 and 2035 ranging from roughly $2.0b to $2.9b, all in dollar terms.

When these projected cash flows are discounted back, the DCF model produces an estimated intrinsic value of about $82.41 per share. Compared with a recent share price around $83.96, this implies the stock is about 1.9% above the model’s estimate, so slightly overvalued on this measure but very close to the DCF fair value.

Result: ABOUT RIGHT

Corteva is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Corteva.

Approach 2: Corteva Price vs Earnings

P/E is a useful yardstick for profitable companies because it links what you pay for each share directly to the earnings that support that share. It helps you see how much the market is willing to pay for each dollar of profit.

What counts as a “normal” P/E depends a lot on growth expectations and risk. Higher expected earnings growth or lower perceived risk can justify a higher multiple, while slower growth or higher risk usually calls for a lower one.

Corteva currently trades on a P/E of 47.25x. That is above both the Chemicals industry average of 28.23x and the broader peer average of 20.60x, which suggests investors are willing to pay a premium compared with many similar companies.

Simply Wall St’s Fair Ratio, at 27.32x, is a proprietary estimate of what Corteva’s P/E might look like after considering factors such as earnings growth, industry, profit margins, market cap and risk profile. This tends to be more tailored than a simple comparison with peers or industry averages because those benchmarks do not fully adjust for these company specific traits.

Comparing the Fair Ratio of 27.32x with the current P/E of 47.25x implies Corteva is trading above this model based estimate.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Corteva Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St’s Community page let you attach your own story about Corteva, including what you think happens to its revenue, earnings and margins, to a set of forecasts and a fair value that you can compare directly to today’s price. The numbers update automatically as fresh news or results come in. Some investors may build a more optimistic Corteva Narrative that lines up with the higher US$95.00 analyst fair value, while others may prefer a more cautious version closer to US$74.00. Both views sit side by side so you can quickly see how different assumptions lead to different fair values and help you decide whether the current price looks attractive or not for you.

Do you think there's more to the story for Corteva? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com